By the end of the year, a menopause medication that “switches off” hot flashes might be accessible.

n

By the end of the year, an anti-menopausal drug could be available that “turns off” hot flashes in just days.

The ‘game-changing’ drug, called fezolinetant, acts directly on the brain and could be a lifeline for hundreds of thousands of women unable to take hormone replacement therapy (HRT).

Earlier this month, the US approved fezolinetant, the first non-hormonal menopause drug.

Its makers describe it as a therapy “based on our understanding of the biology behind hot flashes.”

The drug works by blocking a brain protein called neurokinin 3, which plays a role in regulating body temperature in menopausal women.

n

n

An anti-menopausal drug that 'turns off' hot flashes in just days could be available by the end of the year (file image)

An anti-menopausal drug that ‘turns off’ hot flashes in just days could be available by the end of the year (file image)

n

n

The 'groundbreaking' drug, called fezolinetant, could be a lifeline for hundreds of thousands of women unable to take hormone replacement therapy (HRT) (file image)

The 'groundbreaking' drug, called fezolinetant, could be a lifeline for hundreds of thousands of women unable to take hormone replacement therapy (HRT) (file image)

The ‘groundbreaking’ drug, called fezolinetant, could be a lifeline for hundreds of thousands of women unable to take hormone replacement therapy (HRT) (file image)

A large study published this year found that taking the pill once a day for 12 weeks reduced the frequency of hot flashes by about 60 percent in women with moderate or severe symptoms, compared with a 45 percent decrease in those taking a placebo. got.

Women also reported a reduction in hot flash severity and better sleep quality.

“This is going to be a complete blockbuster drug,” said Professor Waljit Dhillo, an endocrinologist at Imperial College London.

“It’s like a switch. Within a day or two the hot flashes disappear – it’s amazing how well these drugs work.

“It will completely change for many women.”

Fezolinetant, made by the Japanese company Astellas Pharma, is now under review by the European Medicines Agency.

A decision is expected this year, followed by the UK several months later.

The drug does not affect estrogen levels – which drop sharply during menopause – so will not address symptoms of fatigue and mood swings the way HRT does.

But HRT isn’t for everyone, including people with a history of breast or ovarian cancer.

‘If you can’t take HRT, there aren’t many really effective options,’ says Professor Annice Mukherjee, a consultant endocrinologist at Coventry University. “Women need options.”

https://healthmedicinet.com/i/by-the-end-of-the-year-a-menopause-medication-that-switches-off-hot-flashes-might-be-accessible/